Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
|
|
|
- Phebe Hart
- 5 years ago
- Views:
Transcription
1 Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) Age (years) 57 ± ± Hypertension (%) 33 (92) 71 (89) Smoking (%) 7 (19) 28 (35) Diabetes (%) 10 (28) 26 (33) AMI (%) 13 (36) 42 (53) Unstable angina (%) 23 (64) 38 (47) Stroke (%) 5 (14) 4 (5) PVD (%) 5 (14) 7 (9) BMI (Kg/m 2 ) 29.7 ± ± Waist circumference (cm) ± ± Systolic arterial pressure (mmhg) 130 ( ) 130 ( ) Diastolic arterial pressure (mmhg) 81 ± ± Heart rate (bpm) 66 ± ± Gensini score (au) 18 (2-41) 21 (0-33) Gensini median (%) 14 (47) 28 (53) FMD (%) 11.5 ( ) 12.3 ( ) EIR (%) 14.5 ± ± compared by the chi-square test or the Fisher s exact test; numerical variables compared by Student s t-test or the Mann-Whitney test. AMI: acute myocardial Supplementary table 2 Laboratory characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Total cholesterol (mg/dl) 188 ± ± HDL-c (mg/dl) 39 ± 9 39 ± LDL-c (mg/dl) 114 ± ± Triglycerides (mg/dl) 174 ( ) 161 ( ) Apolipoprotein A1 (mg/dl) 104 ± ± Apolipoprotein B (mg/dl) 113 ± ± ApoB / ApoA ± ± Lipoprotein (a) (mg/dl) 35 (9-67) 32 (16-75) Creatinine (mg/dl) 1.0 ( ) 1.0 ( ) Glycemia (mg/dl) 120 ± ± HbA1c (%) 5.7 ( ) 6.1 ( ) Mean baseline insulin (µui/l) 13 (9-20) 12 (8-19) Hs-CRP (mg/l) 12.8 ( ) 7.0 ( ) TBARS (ηmol/ml plasma) 1.6 ± ± Adiponectin (ng/ml) 6158 ± ± Albuminuria (mg/l) 3.67 ( ) 2.11 ( ) 0.515
2 Supplementary table 3 Demographic and clinical characteristics of participants by methylenotetrahydrofolate reductase (MTHFR) gene polymorphisms CC CT/TT n = 36 n = 79 Men (%) 24 (67) 50 (63) Age (years) 56 ± 9 56 ± Hypertension (%) 34 (94) 69 (87) Smoking (%) 12 (33) 23 (29) Diabetes (%) 9 (25) 26 (33) AMI (%) 11 (30) 26 (33) Unstable angina (%) 15 (42) 46 (58) Stroke (%) 2 (6) 7(9) PVD (%) 4 (11) 7 (9) BMI (Kg/m 2 ) 31.3 ± ± Waist circumference (cm) ± ± Systolic arterial pressure (mmhg) 130 ( ) 130 ( ) Diastolic arterial pressure (mmhg) 84 ± ± Heart rate (bpm) 66 ± ± Gensini score (au) 32 (25-45) 19 (0-35) Gensini median (%) 31 (76) 27 (66) FMD (%) 12.8 ± ± EIR (%) 12 (9-20) 15 (9-20) Supplementary table 4 Laboratory characteristics of participants by methylenotetrahydrofolate reductase (MTHFR) gene polymorphisms CC CT/TT n = 36 n = 79 Total cholesterol (mg/dl) 197 ± ± HDL-c (mg/dl) 39 ± 7 38 ± LDL-c (mg/dl) 124 ± ± Triglycerides (mg/dl) 158 ( ) 173 ( ) Apolipoprotein A1 (mg/dl) 110 ± ± Apolipoprotein B (mg/dl) 117 ± ± ApoB / ApoA ± ± Lipoprotein (a) (mg/dl) 34 (18-68) 33 (15-75) Creatinine (mg/dl) 1.0 ( ) 1.0 ( ) Glycemia (mg/dl) 104 (97-127) 108 (96-138) HbA1c (%) 5.7 ( ) 6.0 ( ) Mean baseline insulin (µui/l) 13 ± 8 15 ± Hs-CRP (mg/l) 7.2 ( ) 10.4 ( ) TBARS (ηmol/ml plasma) 1.6 ± ± Adiponectin (ng/ml) 4990 ± ± Albuminuria (mg/l) 2.40 ( ) 3.37 ( ) 0.919
3 Supplementary table 5 Demographic and clinical characteristics of participants by endothelial nitric oxide synthase (ENOS) gene polymorphisms GG GT/TT n = 10 n = 106 Men (%) 9 (90) 65 (61) Age (years) 55 ± 6 56 ± Hypertension (%) 10 (100) 94 (89) Smoking (%) 5 (50) 30 (28) Diabetes (%) 0 (0) 36 (34) AMI (%) 7 (70) 48 (45) Unstable angina (%) 3 (30) 58 (55) Stroke (%) 0 (0) 9 (8) PVD (%) 2 (20) 10 (9) BMI (Kg/m 2 ) 28.7 ± ± Waist circumference (cm) ± ± Systolic arterial pressure (mmhg) 128 ± ± Diastolic arterial pressure (mmhg) 86 ± ± Heart rate (bpm) 67 ± ± Gensini score (au) 23 (0-46) 21 (1-35) Gensini median (%) 3 (50) 39 (51) FMD (%) 11.0 ± ± EIR (%) 18.2 ( ) 14.0 ( ) Supplementary table 6 Laboratory characteristics of participants by endothelial nitric oxide synthase (ENOS) gene polymorphisms GG GT/TT n = 10 n = 106 Total cholesterol (mg/dl) 194 ± ± HDL-c (mg/dl) 37 ± 6 41 ± LDL-c (mg/dl) 118 ± ± Triglycerides (mg/dl) 173 ( ) 159 ( ) Apolipoprotein A1 (mg/dl) 108 ± ± Apolipoprotein B (mg/dl) 125 ± ± ApoB / ApoA ± ± Lipoprotein (a) (mg/dl) 23 (8-61) 34 (16-75) Creatinine (mg/dl) 1.0 ( ) 1.0 ( ) Glycemia (mg/dl) 106 ± ± HbA1c (%) 5.9± ± Mean baseline insulin (µui/l) 13 (9-17) 12 (9-19) Hs-CRP (mg/l) 7.3 ( ) 10.2 ( ) TBARS (ηmol/ml plasma) 1.5 ( ) 1.6 ( ) Adiponectin (ng/ml) 2148 ( ) 5010 ( ) Albuminuria (mg/l) 1.55 ( ) 2.56 ( ) 0.796
4 Supplementary table 7 Demographic and clinical characteristics of participants by angiotensin-converting enzyme (ACE) gene polymorphisms II ID/DD n = 17 n = 99 Men (%) 10 (59) 64 (65) Age (years) 56 ± 8 56 ± Hypertension (%) 16 (94) 88 (89) Smoking (%) 6 (35) 29 (29) Diabetes (%) 8 (47) 28 (28) AMI (%) 10 (59) 45 (45) Unstable angina (%) 7 (41) 54 (55) Stroke (%) 0 (0) 9 (9) PVD (%) 3 (18) 9 (9) BMI (Kg/m 2 ) 31.9 ± ± Waist circumference (cm) ± ± Systolic arterial pressure (mmhg) 130 ( ) 130 ( ) Diastolic arterial pressure (mmhg) 83 ± ± Heart rate (bpm) 65 ± ± Gensini score (au) 19 (0-34) 21 (1-38) Gensini median (%) 5 (50) 37 (51) FMD (%) 12.7 ± ± EIR (%) 10.6 ( ) 15.1 ( ) Supplementary table 8 Laboratory characteristics of participants by angiotensin-converting enzyme (ACE) gene polymorphisms II ID/DD n = 17 n = 99 Total cholesterol (mg/dl) 179 ± ± HDL-c (mg/dl) 39 (32-43) 39 (34-46) LDL-c (mg/dl) 107 ± ± Triglycerides (mg/dl) 152 ( ) 167 ( ) Apolipoprotein A1 (mg/dl) 105 ± ± Apolipoprotein B (mg/dl) 107 ± ± ApoB / ApoA ± ± Lipoprotein (a) (mg/dl) 29 (20-54) 33 (12-76) Creatinine (mg/dl) 1.0 ( ) 1.0 ( ) Glycemia (mg/dl) 112 (99-187) 106 (95-138) HbA1c (%) 6.1 ( ) 5.8 ( ) Mean baseline insulin (µui/l) 10.5 ( ) 13.0 ( Hs-CRP (mg/l) 11.7 ( ) 8.7 ( ) TBARS (ηmol/ml plasma) 1.8 ± ± Adiponectin (ng/ml) 6478 ± ± Albuminuria (mg/l) 1.20 ( ) 3.33 ( ) Apo: apolipoprotein; HbA1c: glycated hemoglobin; HDL-c, high density lipoprotein; LDL-C: low density lipoprotein; hs-crp: high-sensitivity C-reactive protein;
5 Supplementary table 9 Demographic and clinical characteristics of participants by angiotensin II type 1 receptor (AT1R) gene polymorphisms AA AC/CC n = 70 n = 46 Men (%) 42 (60) 32 (70) Age (years) 57 ± 9 56 ± Hypertension (%) 64 (91) 40 (87) Smoking (%) 21 (30) 14 (30) Diabetes (%) 20 (29) 16 (35) AMI (%) 34 (49) 21 (46) Unstable angina (%) 36 (51) 25 (54) Stroke (%) 6 (9) 3 (7) PVD (%) 8 (11) 4 (9) BMI (Kg/m 2 ) 30.2 ± ± Waist circumference (cm) ± ± Systolic arterial pressure (mmhg) 132 ± ± Diastolic arterial pressure (mmhg) 86 ± ± Heart rate (bpm) 71 ± ± Gensini score (au) 21 (0-35) 21 (1-40) Gensini median (%) 24 (50) 18 (51) FMD (%) 13.8 ± ± EIR (%) 15.6 ( ) 13.2 ( ) Supplementary table 10 Laboratory characteristics of participants by angiotensin II type 1 receptor (AT1R) gene polymorphisms AA AC/CC n = 70 n = 46 Total cholesterol (mg/dl) 192 ± ± HDL-c (mg/dl) 41 ± 9 40 ± LDL-c (mg/dl) 118 ± ± Triglycerides (mg/dl) 158 ( ) 167 ( ) Apolipoprotein A1 (mg/dl) 109 ± ± Apolipoprotein B (mg/dl) 115 ± ± ApoB / ApoA ± ± Lipoprotein (a) (mg/dl) 32 (15-57) 34 (17-90) Creatinine (mg/dl) 1.0 ( ) 1.0 ( ) Glycemia (mg/dl) 107 (97-153) 105 (95-127) HbA1c (%) 6.6 ± ± Mean baseline insulin (µui/l) 13.0 ( ) 11.3 ( ) Hs-CRP (mg/l) 9.0 ( ) 10.5 ( ) TBARS (ηmol/ml plasma) 1.6 ± ± Adiponectin (ng/ml) 5968 ± ± Albuminuria (mg/l) 1.82 ( ) 3.33 ( ) 0.990
6 Supplementary table 11 Demographic and clinical characteristics of participants by apolipoprotein C3 (APOC3) gene polymorphisms S1S1/S1S2 S2S2 n = 35 n = 81 Men (%) 20 (57) 54 (67) Age (years) 56 ± 8 56 ± Hypertension (%) 31 (89) 73 (90) Smoking (%) 10 (29) 25 (31) Diabetes (%) 8 (23) 28 (35) AMI (%) 17 (49) 38 (47) Unstable angina (%) 18 (51) 38 (47) Stroke (%) 4 (11) 5 (6) PVD (%) 5 (14) 7 (9) BMI (Kg/m 2 ) 29.5 ± ± Waist circumference (cm) ± ± Systolic arterial pressure (mmhg) 130 ( ) 130 ( ) Diastolic arterial pressure (mmhg) 90 ± ± Heart rate (bpm) 70 ± ± Gensini score (au) 20 (1-40) 21 (0-35) Gensini median (%) 11 (48) 31 (52) FMD (%) 11.5 ± ± EIR (%) 15.1 ( ) 14.8 ( ) Supplementary table 12 Laboratory characteristics of participants by apolipoprotein C3 (APOC3) gene polymorphisms S1S1/S1S2 S2S2 n = 35 n = 81 Total cholesterol (mg/dl) 189 ± ± HDL-c (mg/dl) 41 ± 9 40 ± LDL-c (mg/dl) 114 ± ± Triglycerides (mg/dl) 158 ( ) 168 ( ) Apolipoprotein A1 (mg/dl) 111 ± ± Apolipoprotein B (mg/dl) 112 ± ± ApoB / ApoA ± ± Lipoprotein (a) (mg/dl) 26 (10-67) 34 (18-75) Creatinine (mg/dl) 0.9 ( ) 1.0 ( ) Glycemia (mg/dl) 106 (97-138) 107 (96-138) HbA1c (%) 5.8 ( ) 5.9 ( ) Mean baseline insulin (µui/l) 13.3 ( ) 12.2 ( Hs-CRP (mg/l) 8.1 ( ) 10.5 ( ) TBARS (ηmol/ml plasma) 1.6 ± ± Adiponectin (ng/ml) 5269 ± ± Albuminuria (mg/l) 3.00 ( ) 2.40 ( ) 0.981
7 Supplementary table 13 Demographic and clinical characteristics of participants by lipoprotein lipase (LPL) gene polymorphisms DD DN/NN n = 17 n = 99 Men (%) 13 (77) 61 (62) Age (years) 5 ± 9 56 ± Hypertension (%) 14 (82) 90 (91) Smoking (%) 7 (41) 28 (28) Diabetes (%) 5 (29) 31 (31) AMI (%) 9 (53) 46 (47) Unstable angina (%) 8 (47) 53 (53) Stroke (%) 1 (6) 8 (8) PVD (%) 0 (0) 12 (12) BMI (Kg/m 2 ) 29.0 ± ± Waist circumference (cm) ± ± Systolic arterial pressure (mmhg) 129 ± ± Diastolic arterial pressure (mmhg) 79 ± ± Heart rate (bpm) 68 ± ± Gensini score (au) 30 (13-51) 18 (0-35) Gensini median (%) 10 (77) 32 (46) FMD (%) 16.8 ± ± EIR (%) 16.8 ( ) 14.2 ( ) Supplementary table 14 Laboratory characteristics of participants by lipoprotein lipase (LPL) gene polymorphisms DD DN/NN n = 17 n = 99 Total cholesterol (mg/dl) 198 ± ± HDL-c (mg/dl) 38 (32-43) 39 (34-46) LDL-c (mg/dl) 118 ± ± Triglycerides (mg/dl) 194 ( ) 158 ( ) Apolipoprotein A1 (mg/dl) 109 ± ± Apolipoprotein B (mg/dl) 122 ± ± ApoB / ApoA ( ) 1.03 ( ) Lipoprotein (a) (mg/dl) 33 (16-49) 33 (16-76) Creatinine (mg/dl) 1.0 ( ) 1.0 ( ) Glycemia (mg/dl) 106 (95-150) 107 (97-138) HbA1c (%) 5.7 ( ) 5.9 ( ) Mean baseline insulin (µui/l) 10.7 ( ) 13.3 ( ) Hs-CRP (mg/l) 10.2 ( ) 9.9 ( ) TBARS (ηmol/ml plasma) 1.8 ± ± Adiponectin (ng/ml) 6241 ± ± Albuminuria (mg/l) 0.84 ( ) 2.78 ( ) 0.273
8 Supplementary table 15 Distribution of Gensini score in patients with metabolic syndrome and recent acute coronary syndrome Gensini scorre N 83 Mean 24 Median 21 Standard deviation 24.0 Minimum 0 Maximum 96 Asymmetry Kurtosis P P
Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
Know Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
Supplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
egfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures
Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2
Supplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
CVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
DM type. Diagnostic method of DR. fluorescein angiography; Ophthalmoscopy. ophthalmoscopic examination. fundus photography; Ophthalmoscopy
2012 Informa USA, Inc. DOI: 10.3109/13816810.2012.675398 Online supplementary material published in conjunction with S. Zhao et al.., Nitric oxide synthase 3 (NOS3) 4b/a, T-786C and G894T polymorphisms
Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).
Table S1. Characteristics associated with frequency of nut (full entire sample; Nn=4,416). Daily nut Nn= 212 Weekly nut Nn= 487 Monthly nut Nn= 1,276 Infrequent or never nut Nn= 2,441 Sex; n (%) men 52
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
Methods. Background and Objectives STRADIVARIUS
STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with
Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with Insulin Resistance Mehrnoosh Shanaki, Ph.D. Assistant Professor of Clinical Biochemistry Shahid Beheshti
LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME
LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME Diana A. Chirinos, Ronald Goldberg, Elias Querales-Mago, Miriam Gutt, Judith R. McCalla, Marc Gellman and Neil Schneiderman
Correlation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
Central pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
Statistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study
1.0 Page 1 of 15 FINAL DexComG4 (DexCom Corporation) CGMMDI GOLD-Study monitoring (CGM) in individuals with type 1 diabetes treated 2016-07-07 Approvals Name/Title: Nils-Gunnar Pehrsson / Statistiska Konsultgruppen,
Supplementary Online Content
Supplementary Online Content McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol.
Deprivation Study. The Freiburg Study
The Freiburg Study Deprivation Study Free Radicals Inflammation (hs-crp) Blood Pressure (Systolic, Diastolic) Blood Lipids (Cholesterol, Triglycerides) Energy Utilization (Heart Rate) Sugar Metabolism
Heart Online First, published on March 29, 2005 as /hrt SCIENTIFIC LETTER
Heart Online First, published on March 29, 2005 as 10.1136/hrt.2004.056523 Manuscript ID: HEARTJNL/2004/056523 March 18, 2005 SCIENTIFIC LETTER Effects of HMG-CoA Reductase Inhibition on Endothelial Function
Supplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC
Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT
Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery
300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
SCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
SYNOPSIS. Abbreviated Clinical Study Report. Study Code: RIMON_L_01031 Document Status: Synopsis V 2.1 Date: 16-Oct Title of the study:
SYNOPSIS Title of the study: Investigator(s): A 12-month multicentre, randomised, double-blind, placebo-controlled study with two parallel groups to assess the effects of rimonabant 20 mg in patients with
ASSeSSing the risk of fatal cardiovascular disease
ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril
Nature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
Replacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins
Replacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins Muller H, Jordal O, et al. (998) Replacement of partially hydrogenated soybean
SUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
SUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
Association between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
4. resisted training ** OR resistance training * OR resisted exercise ** OR resistance exercise ** OR strength training ** OR strength exercise **
Supplementary Table 1. Search strategy (up to January 10 th 2015). MEDLINE Result: 253 studies 1. clinical trial ** OR controlled trial ** OR randomized controlled trial * OR randomised controlled trial
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
Supplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
HEART RATE IN PATIENTS WITH CORONARY ARTERY DISEASE IN LATVIA
Inga Balode HEART RATE IN PATIENTS WITH CORONARY ARTERY DISEASE IN LATVIA Summary of the Doctoral Thesis for obtaining the degree of a Doctor of Medicine Speciality Internal Medicine Riga, 2014 Doctoral
METABOLISM of ADIPOSE TISSUE
METABOLISM of ADIPOSE TISSUE 2. LF UK Prof. Rudolf Poledne, PhD. TYPES OF ADIPOSE TISSUE brown adipose tissue subcutaneous adipose tissue visceral adipose tissue ADIPOSE TISSUE FUNCTIONS: thermal isolation
Är dagens troponinmetoder tillräckligt känsliga?
Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital
John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
Supplementary Online Content
Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA
Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
SUPPLEMENTAL MATERIAL. Number of patients 14
SUPPLEMENTAL MATERIAL Supplemental Table 1 Number of patients 14 Age, years 54.9 ± 10.0 Female gender, n (%) 6 (42.9) Diabetes, n (%) 2 (14.3) History of hypertension, n (%) 5 (35.7) Ever smoker, n (%)
Novel Markers of Arterial Dysfunction
혈관연구회창립심포지움, 3 월 3 일, 2005 Novel Markers of Arterial Dysfunction Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon Medical School Incheon, Korea Atherosclerosis: A progressive process PHASE I: Initiation
Supplementary Note Details of the patient populations studied Strengths and weakness of the study
Supplementary Note Details of the patient populations studied TVD and NCA patients. Patients were recruited to the TVD (triple vessel disease) group who had significant coronary artery disease (defined
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
Pathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia
Page 1 Sponsor Novartis Generic Drug Name Fluvastatin Therapeutic Area of Trial Dyslipidemia Approved Indication Therapeutic area and approved indications in Germany: Hypercholesterolemia (HC), combined
Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study
Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study Authors: Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DC, Reynolds MR, Lewis BA, Cerezo J, Oldenburg
Cardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
Table S2: Anthropometric, clinical, cardiovascular and appetite outcome changes over 8 weeks (baseline-week 8) by snack group
Table S1: Nutrient composition of cracker and almond snacks Cracker* Almond** Weight, g 77.5 g (5 sheets) 56.7 g (2 oz.) Energy, kcal 338 364 Carbohydrate, g (kcal) 62.5 12.6 Dietary fiber, g 2.5 8.1 Protein,
pulmonary artery vasoreactivity in patients with idiopathic pulmonary arterial hypertension
Supplementary material Jonas K, Magoń W, Waligóra M, et al. High density lipoprotein cholesterol levels and pulmonary artery vasoreactivity in patients with idiopathic pulmonary arterial hypertension Pol
By: Dr Mehrnoosh Shanaki
Resveratrol could partly improve the crosstalk between canonical β-catenin/wnt and FOXO pathways in coronary artery disease patients with metabolic syndrome: A case control study By: Dr Mehrnoosh Shanaki
Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups
Supplemental Table S1: Unadjusted and Adjusted Hazard Ratios for Diabetes Associated with Baseline Factors Considered in Model 3 SMART Participants Only Unadjusted Adjusted* Baseline p-value p-value Covariate
Gender: M Chart No: Fasting: Yes. Boston Heart HDL Map TM Test 1 ApoA-I (mg/dl) levels in HDL particles. α Range > <14 mg/dl. α-2 50.
Pro vider: Ordering Provider 123 Main Street Anytown, ST 12345 Account No: DOB: 00/00/1950 Framingham Risk Score: Patient Info: FAMILY HIST CVD Lipid, Lipoprotein and Apolipoprotein Tests Total Cholesterol
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
Metabolic Syndrome and Workplace Outcome
Metabolic Syndrome and Workplace Outcome Maine Worksite Wellness Initiative June 15, 2010 Alyssa B. Schultz Dee W. Edington Current Definition* of Metabolic Syndrome At least 3 of the following: Waist
Seung-Hwan Lee, M.D., Ph.D.
2015.10.16. ICDM, DMJ session Statin discontinuation after achieving a target low-density lipoprotein cholesterol level in type 2 diabetic patients without cardiovascular disease: a randomized controlled
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
Tracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose
DECLARATION OF CONFLICT OF INTEREST Nothing to disclose Four-Year Clinical Outcomes of the OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis; evaluation by IntraVascular UltraSound
Clinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight
Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight Quest, Quest Diagnostics, the associated logo, and all associated Quest Diagnostics marks are the registered trademarks of Quest
Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
C-Reactive Protein and Your Heart
C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory
Need Help.. 4. Resources Abbreviations used in the FH Registry Eligibility Criteria for Inclusion in the FH Registry..
The purpose of the National Familial Hypercholesterolaemia Registry is to collate data to facilitate clinical service planning and to inform clinical best practice. The Registry will also enable research
KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
Supplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
Bariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
COMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI
COMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI WITH TRADITIONAL LIPID MEASURES IN WOMEN DIAGNOSED WITH ACUTE CORNONARY SYNDROMES A PRELIMINARY REPORT. Magdalena Krintus, Katarzyna
Case Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
CRP and fibrinogen imply clinical outcome of patients with type-2 diabetes. and coronary artery disease
CRP and fibrinogen imply clinical outcome of patients with type-2 diabetes and coronary artery disease Marijan Bosevski 1, *, Golubinka Bosevska 1, Lily Stojanovska 2, Vasso Apostolopoulos 2, * 1 University
Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh
"Insight Heart" is also available at www.squarepharma.com.bd Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh Coronary heart disease has been emerging as an
Clinical Trial Results Disclosure Synopsis
Clinical Trial Results Disclosure Synopsis Short Title: The SPLENDOR study Name of Sponsor: Takeda Italia S.p.A. Via Elio Vittorini, 129 00144 Rome, Italy Title of Study: Effects of Pioglitazone on endothelial
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
Metabolic Syndrome Modulates Association between Endothelial Lipase and. Lipid/Lipoprotein Plasma Levels in Acute Heart Failure Patients
Metabolic Syndrome Modulates Association between Endothelial Lipase and Lipid/Lipoprotein Plasma Levels in Acute Heart Failure Patients Ines Potočnjak, Matias Trbušić, Sanda Dokoza Terešak, Bojana Radulović,
Clinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan
Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi
Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
902 Biomed Environ Sci, 2014; 27(11):
902 Biomed Environ Sci, 2014; 27(11): 902-906 Letter to the Editor Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type
Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease
Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
Rationale: Objectives: Indication: Diabetes Mellitus, Type 2 Study Investigators/Centers: 300 physicians in 292 clinics Research Methods: Data Source:
GSK Medicine: N/A Study No.: 112255 Title: A Korean, multi-center, nation-wide, cross-sectional, epidemiology study to identify prevalence of diabetic nephropathy in hypertensive patients with type 2 diabetes